Skip to content
  • Debatforum
  • Seneste
  • Populære
  • Bruger
Temaer
  • Light
  • Dark

Kollaps
FORSIDEN
Log ind Opret konto

Genmab — Oktober 2019

Planlagt Fastgjort Låst Flyttet Genmab
1.6k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • SolsenS Offline
    SolsenS Offline
    Solsen
    wrote on sidst redigeret af
    #410

    Jeg ser stadig ikke de kan hente dara i MM. De har på ingen måde bevist de er bedre, hvorfor de får meget svært ved at fortrænge dara.

    1 Reply Last reply
    0
    • BulderB Offline
      BulderB Offline
      Bulder
      wrote on sidst redigeret af
      #411

      Der kan være lidt her: However, one particular difference is that unlike Darzalex, it is not associated with complement activation, meaning it can be more readily given to patients with asthma or chronic obstructive pulmonary disease.
      “It’s not a trivial population,” said Dr. Paul Richardson. https://medcitynews.com/2019/06/sanofis-isatuximab-shines-in-myeloma-at-asco-but-where-will-it-fit-into-treatment/?rf=1

      1 Reply Last reply
      0
      • P Offline
        P Offline
        peter12
        wrote on sidst redigeret af
        #412

        Der kører da forsøg med dara i solide ? https://www.clinicaltrials.gov/ct2/show/NCT03098550?term=daratumumab+solid&rank=2

        1 Reply Last reply
        0
        • SolsenS Offline
          SolsenS Offline
          Solsen
          wrote on sidst redigeret af
          #413

          Jo da men det er et BMS forsøg. Så ikke megen aktivitet fra JNJs side.

          1 Reply Last reply
          0
          • SolsenS Offline
            SolsenS Offline
            Solsen
            wrote on sidst redigeret af
            #414

            Cetrelimab hedder JNJ PD1 https://clinicaltrials.gov/ct2/show/NCT02908906

            1 Reply Last reply
            0
            • S Offline
              S Offline
              Sukkeralf
              wrote on sidst redigeret af
              #415

              Solsen tror absolut heller ikke isatuximab vil erstatte daratumumab, men der kommer trods alt en del Mm drugs på makredet - og hvis enkelte af dem nupper en halv til hel milliard dollars af omsætningen, så kan det være peaksale måske ender 1-3 milliarder dollars lavere i MM

              1 Reply Last reply
              0
              • S Offline
                S Offline
                Sukkeralf
                wrote on sidst redigeret af
                #416

                isatuximab kan eksempelvis begynde at spille på pris, men der er stadig lang vej til de er repræsenteret så bredt som daratumumab er.

                1 Reply Last reply
                0
                • G Offline
                  G Offline
                  GeorgeBest
                  wrote on sidst redigeret af
                  #417

                  de 1-3 milliarder USD kan amyloidosis så passende kompensere for...

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #418

                    My understanding from the last JNJ R&D day was that they would wait with solid until the SC approval

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #419

                      Lebowitz said that in that earlier lung trial the concern was that steroids are taking away from the immune response. He adds: we have developped (and into the clinic) a steroid sparing regimen where we can get the streroids off -and we needed the SC to do that

                      1 Reply Last reply
                      0
                      • E Offline
                        E Offline
                        E_L
                        wrote on sidst redigeret af
                        #420

                        And once we have those pieces in place I think we retest that hypothesis on immunomodulatory properties of darzalex

                        1 Reply Last reply
                        0
                        • E Offline
                          E Offline
                          E_L
                          wrote on sidst redigeret af
                          #421

                          https://edge.media-server.com/mmc/p/jjsewqjm 4:33:30

                          1 Reply Last reply
                          0
                          • S Offline
                            S Offline
                            Sukkeralf
                            wrote on sidst redigeret af
                            #422

                            Jan said earlier that they also needed approval of sc dara in MM first - they didnt want to jepardizy that with deaths in solids I guess

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #423

                              i remember you writing that exact sentence before 😉

                              1 Reply Last reply
                              0
                              • BulderB Offline
                                BulderB Offline
                                Bulder
                                wrote on sidst redigeret af
                                #424

                                Mht BMS-studierne i solide - dara-nivo - er der ikke meget tilbage. Der var vist 3. Det ene er lukket for rekruttering https://www.clinicaltrials.gov/ct2/show/NCT03098550?term=daratumumab+nivolumab&rank=2 Det andet er lukket i dara cohorten https://www.clinicaltrials.gov/ct2/show/NCT02488759?term=daratumumab+nivolumab&rank=4

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #425

                                  So it has been 1 of the other reasons i thought SC approval is so important; it could mean the start of new trials imho...

                                  1 Reply Last reply
                                  0
                                  • E Offline
                                    E Offline
                                    E_L
                                    wrote on sidst redigeret af
                                    #426

                                    then again, who knows now what HexaBody-CD38 will bring? We can assume that it is either more potent of safer -or both , if they go through with it, so maybe a more obvious partner for solid combinations...

                                    1 Reply Last reply
                                    0
                                    • BulderB Offline
                                      BulderB Offline
                                      Bulder
                                      wrote on sidst redigeret af
                                      #427

                                      Tilbage er der kun checkmate 142, som også er lukket for rekruttering, men det kan være fordi de er ved at være færdige. https://www.clinicaltrials.gov/ct2/show/NCT02060188?term=daratumumab+nivolumab&rank=5

                                      1 Reply Last reply
                                      0
                                      • Legolas23L Offline
                                        Legolas23L Offline
                                        Legolas23
                                        wrote on sidst redigeret af
                                        #428

                                        Spændende med BMS-studierne.

                                        1 Reply Last reply
                                        0
                                        • E Offline
                                          E Offline
                                          E_L
                                          wrote on sidst redigeret af
                                          #429

                                          Jan criticizing recent Galapagos deal in the Dutch press , thinks they gave away too much
                                          https://fd.nl/ondernemen/1318588/genmab-topman-galapagos-deal-had-ik-nooit-gedaan#

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind

                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          • First post
                                            Last post
                                          0
                                          • Debatforum
                                          • Seneste
                                          • Populære
                                          • Bruger